Stock CANTA CANTARGIA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cantargia AB

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Real-time Estimate Cboe Europe
Other stock markets
 05:23:54 2024-04-29 am EDT 		5-day change 1st Jan Change
3.428 SEK -0.64% Intraday chart for Cantargia AB -8.36% -8.56%
Apr. 17 Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition CI
Apr. 10 Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,467 5,830 1,850 514.3 686.6 633.7 - -
Enterprise Value (EV) 1 1,317 4,927 1,290 87.65 491.9 690.3 1,291 633.7
P/E ratio -12.9 x -33 x -5.04 x -1.06 x -2.27 x -1.6 x -1.84 x -
Yield - - - - - - - -
Capitalization / Revenue - - - - - - 1.1 x 2.77 x
EV / Revenue - - - - - - 2.23 x 2.77 x
EV / EBITDA -11.8 x -28.9 x -3.52 x -0.23 x -1.72 x -2.47 x -68.8 x 10.9 x
EV / FCF -11,838,851 x -31,323,888 x -3,719,919 x -301,183 x - - - -
FCF Yield -0% -0% -0% -0% - - - -
Price to Book 10.1 x 6.41 x 3.47 x 1.32 x 3.76 x -1.79 x -1.41 x -
Nbr of stocks (in thousands) 72,804 91,092 100,193 166,988 183,687 183,687 - -
Reference price 2 20.15 64.00 18.46 3.080 3.738 3.450 3.450 3.450
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 577.5 228.7
EBITDA 1 -111.6 -170.7 -366.8 -377.9 -286.6 -279.5 -18.76 58.3
EBIT 1 -111.6 -173.9 -370.3 -381.5 -290 -280.2 -120.1 58.3
Operating Margin - - - - - - -20.8% 25.49%
Earnings before Tax (EBT) 1 -110.8 -173.1 -366.5 -371.8 -280 -360.8 -375 -
Net income 1 -110.8 -173.1 -366.5 -371.8 -280 -280.2 -96.04 46.3
Net margin - - - - - - -16.63% 20.24%
EPS 2 -1.560 -1.940 -3.660 -2.900 -1.650 -2.160 -1.872 -
Free Cash Flow -111.3 -157.3 -346.8 -291 - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2023 Q1
Net sales - -
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income - -
Net margin - -
EPS 1 - -0.4500
Dividend per Share - -
Announcement Date 11/11/21 5/23/23
1SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 56.6 657 -
Net Cash position 1 150 903 559 427 195 - - -
Leverage (Debt/EBITDA) - - - - - -0.2025 x -35.02 x -
Free Cash Flow -111 -157 -347 -291 - - - -
ROE (net income / shareholders' equity) -74.5% -33.5% -51.5% -80.6% -100% -92.8% - -
ROA (Net income/ Total Assets) -65.7% -31.7% -48% -69.2% -80.2% -92.8% -4,632% -
Assets 1 168.7 545.8 762.9 537.5 349.3 302 2.073 -
Book Value Per Share 2 2.000 9.980 5.320 2.330 0.9900 -1.930 -2.450 -
Cash Flow per Share - - - - - - - -
Capex - 0.89 0.38 7.09 - - - -
Capex / Sales - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.45 SEK
Average target price
12.67 SEK
Spread / Average Target
+267.15%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CANTARGIA AB Stock Cantargia AB
-8.56% 57.8M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+0.79% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-7.98% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CANTA Stock
  4. Financials Cantargia AB